Upgrade to SI Premium - Free Trial

Raymond James looks for further durability in BMY's (BMY) MountainTAP-30 trial

March 16, 2026 4:28 PM
Raymond James analyst Sean McCutcheon reiterated a Market Perform rating on Bristol-Myers Squibb Co. (NYSE: BMY)The analyst commented, "Monday, at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments